



P6:107

Circulating Transforming Growth Factor-Beta1 Levels in Pediatric Bone Sarcoma Patients

Neriman Sari¹, Çigdem Sonmez Atay², Nilgun Kurucu², Inci Ergurhan Ilhan²

¹Ankara Oncology Hospital ², Turkey

Background

Transforming growth factor-Beta (TGF-B1) has an important role in wound healing, angiogenesis, immunoregulation and cancer. TGF-beta plays a major role in cancer by suppressing tumor growth in the early phase of neoplasia, while promoting tumor progression and metastasis in later phases. We aimed to identify the clinical significance of circulating levels of TGF-beta1 as a tumor marker in bone sarcomas.

Methods

Serum TGF-B1 levels were measured by ELISA in sera of 31 patients with osteosarcoma, 14 patients with Ewing sarcoma before and after treatment and 22 healthy controls.

Results

Pretreatment mean serum TGF-beta 1 levels were 44,8 ng/ml in osteosarcoma, 46,2 ng/ml in ewing sarcoma and 45.4 ng/ml in control groups. Posttreatment mean serum TGF-beta 1 levels were 42,2 ng/ml in osteosarcoma, 41,2 ng/ml in ewing sarcoma group. Serum TGF-beta 1 level in metastatic disease was 48.1 ng/ml, in non metastatik disease 44,5 ng/ml. The differences between groups and pre and post treatment levels were not significant statistically.

Conclusion

We could not find any diagnostic and prognostic value of TGF beta 1 in pediatric bone sarcomas.

E-mail (main author): neriman@meddata.com.tr